Effect of Pyran on Latency After Herpes Simplex Virus Infections
Open Access
- 1 April 1979
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 15 (4), 547-553
- https://doi.org/10.1128/aac.15.4.547
Abstract
The immunomodulator pyran protected mice against both herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections. In infections of the lip with HSV-1, prophylactic administration of pyran reduced the severity of the herpetic lesions and enhanced their resolution, but did not decrease the high incidence of development of latent HSV-1 infection of the trigeminal ganglia. In vaginal infections with HSV-2, prophylactic administration of pyran either systemically or locally reduced mortality, reduced the incidence of mice with vaginal HSV-2 infection, and did not alter the low incidence of latent infection of the spinal dorsal root ganglia. Pyran treatment before systemic herpetic infection after intravenous inoculation of HSV-2 also reduced mortality and virus replication, as evidenced by a decreased antibody response in the survivors, and it either reduced latent infection in the spinal dorsal root ganglia or did not predispose mice to latent infection. Treatment with the immunomodulator appeared to inhibit or reduce HSV infection early in viral pathogenesis in all three model systems, producing protection from clinical disease and resulting in less virus to induce a systemic antibody response, with either a reduction in latent virus infection or no enhancement of development of latency. In all of the HSV models, the development of latent herpetic infection was closely correlated with sufficient virus replication early in the infection to induce a systemic neutralizing-antibody response.This publication has 27 references indexed in Scilit:
- Effect of Treatment with Exogenous Interferon, Polyriboinosinic-Polyribocytidylic Acid, or Polyriboinosinic-Polyribocytidylic Acid-Poly-L-Lysine Complex on Herpesvirus hominis Infections in MiceThe Journal of Infectious Diseases, 1978
- Resistance to vaginal or systemic infection with herpes simplex virus type 2Archiv für die gesamte Virusforschung, 1978
- ANTIVIRAL POTENTIAL OF PHOSPHONOACETIC ACIDAnnals of the New York Academy of Sciences, 1977
- Effect of Immunization on Acute and Latent Infections of Vaginouterine Tissue with Herpes Simplex Virus Types 1 and 2The Journal of Infectious Diseases, 1977
- Genital Herpesvirus hominis Infection in Mice. II. Treatment with Phosphonoacetic Acid, Adenine Arabinoside, and Adenine Arabinoside 5'-MonophosphateThe Journal of Infectious Diseases, 1977
- Immunological response restricts number of cells in sensory ganglia infected with herpes simplex virusNature, 1976
- Effect of 9-, -D-Arabinofuranosylhypoxanthine 5'-Monophosphate on Genital Lesions and Encephalitis Induced by Herpesvirus hominis Type 2 in Female MiceThe Journal of Infectious Diseases, 1976
- Latent Herpetic Infections Following Experimental ViraemiaJournal of General Virology, 1976
- Enhanced Host Defense Mechanisms with Levamisole in Suckling RatsThe Journal of Infectious Diseases, 1975
- Latent Infection of Sensory Ganglia with Herpes Simplex Virus: Efficacy of ImmunizationScience, 1975